The initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Novo Nordisk, Pfizer, and Shionogi & Co., Ltd.
BioCelerate is led by the Chief Executive Officer of TransCelerate, Dalvir Gill, PhD. For more on Dr. Gill, please see his bio on the TransCelerate leadership page. BioCelerate is a subsidiary of TransCelerate BioPharma, and draws upon separate funding and support. In order to participate in BioCelerate it is necessary to be a Member Company of TransCelerate BioPharma, Inc. TransCelerate membership is available to biopharmaceutical research and development organizations who engage in innovative discovery, development and manufacturing of new drugs. Information about membership and a membership application is available on the TransCelerate website. BioCelerate initiatives are approved by a Governing Council comprised of representatives from participating BioCelerate Companies.
In case you missed it, check out the recordings from our two recent webinars: